Personalized mRNA vaccine trial aims to stop kidney Cancer's return
NCT ID NCT06307431
Summary
This study is testing whether adding a personalized mRNA vaccine (V940) to a standard immunotherapy drug (pembrolizumab) is better at preventing kidney cancer from coming back after surgery than the immunotherapy drug alone. It involves about 272 people who have had surgery for intermediate to high-risk kidney cancer. The main goal is to see if the combination helps people live longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center ( Site 0107)
Philadelphia, Pennsylvania, 19104, United States
-
Addenbrooke's Hospital ( Site 1004)
Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom
-
Ankara Universitesi Tip Fakultesi Hastanesi-Oncology ( Site 0902)
Ankara, Turkey (Türkiye)
-
Asan Medical Center ( Site 1602)
Seoul, 05505, South Korea
-
Asklepios Altona-Department of Urology ( Site 0410)
Hamburg, 22763, Germany
-
Asociación de Beneficencia Hospital Sirio Libanés ( Site 1110)
Buenos Aires, Buenos Aires F.D., C1419AHN, Argentina
-
Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 0504)
Florence, Tuscany, 50134, Italy
-
Azienda Ospedaliero Universitaria di Parma ( Site 0503)
Parma, 43126, Italy
-
BC Cancer Vancouver ( Site 0005)
Vancouver, British Columbia, V5Z 4E6, Canada
-
Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 0109)
Boston, Massachusetts, 02215, United States
-
Bradfordhill-Clinical Area ( Site 1201)
Santiago, Region M. de Santiago, 8420383, Chile
-
CENTRE LEON BERARD ( Site 0305)
Lyon Cedex08, Auvergne-Rhône-Alpes, 69373, France
-
CHU Besançon ( Site 0302)
Besançon, Doubs, 25030, France
-
CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 0008)
Québec, Quebec, G1R 2J6, Canada
-
Centro Privado de RMI Rio Cuarto ( Site 1104)
Río Cuarto, Córdoba Province, X5800ALB, Argentina
-
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 0701)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
-
Chang Gung Memorial Hospital at Kaohsiung-Oncology and Hematology ( Site 1701)
Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan
-
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0401)
Berlin, 10117, Germany
-
China Medical University Hospital-Department of Urology ( Site 1702)
Taichung, 40447, Taiwan
-
City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104)
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute-GU ( Site 0101)
Boston, Massachusetts, 02215, United States
-
Duke Cancer Institute ( Site 0106)
Durham, North Carolina, 27710, United States
-
Ege Universitesi Hastanesi-Medical Oncology ( Site 0903)
Izmir, 35100, Turkey (Türkiye)
-
FALP-UIDO ( Site 1202)
Santiago, Region M. de Santiago, 7500921, Chile
-
Fiona Stanley Hospital-Medical Oncology ( Site 1503)
Murdoch, Western Australia, 6150, Australia
-
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0500)
Milan, Lombardy, 20133, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0501)
Rome, Lazio, 00168, Italy
-
Fox Chase Cancer Center ( Site 0111)
Philadelphia, Pennsylvania, 19111, United States
-
Fundacion Estudios Clinicos ( Site 1111)
Rosario, Santa Fe Province, S2000CEJ, Argentina
-
Gartnavel General Hospital-Clinical Trials Unit ( Site 1002)
Glasgow, Glasgow City, G12 0YN, United Kingdom
-
Gustave Roussy ( Site 0304)
Villejuif, Île-de-France Region, 94805, France
-
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 0802)
Seville, 41013, Spain
-
Hacettepe Universite Hastaneleri-oncology hospital ( Site 0901)
Ankara, 06230, Turkey (Türkiye)
-
Hospital Británico de Buenos Aires-Oncology ( Site 1106)
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1280AEB, Argentina
-
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0800)
Barcelona, 08035, Spain
-
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0801)
Madrid, Madrid, Comunidad de, 28034, Spain
-
Hôpital Européen Georges Pompidou ( Site 0300)
Paris, 75015, France
-
Institut Claudius Regaud ( Site 0303)
Toulouse, Haute-Garonne, 31059, France
-
Instituto Alexander Fleming-Alexander Fleming ( Site 1101)
Buenos Aires, Buenos Aires F.D., 1426ANZ, Argentina
-
Klinikum Stuttgart - Katharinenhospital ( Site 0400)
Stuttgart, Baden-Wurttemberg, 70174, Germany
-
Macquarie University-MQ Health Clinical Trials Unit ( Site 1502)
Macquarie University, New South Wales, 2109, Australia
-
Memorial Sloan Kettering Cancer Center ( Site 0100)
New York, New York, 10065, United States
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( S
Warsaw, Masovian Voivodeship, 02-781, Poland
-
ONCOCENTRO APYS-ACEREY ( Site 1200)
Viña del Mar, Región de Valparaíso, 2520598, Chile
-
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 1205)
Santiago, Region M. de Santiago, 8330073, Chile
-
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
Brisbane, Queensland, 4029, Australia
-
Samsung Medical Center ( Site 1601)
Seoul, 06351, South Korea
-
Seoul National University Hospital ( Site 1600)
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System ( Site 1603)
Seoul, 03722, South Korea
-
St Bartholomew's Hospital ( Site 1000)
London, London, City of, EC1A 7BE, United Kingdom
-
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0702)
Koszalin, West Pomeranian Voivodeship, 75-581, Poland
-
Taichung Veterans General Hospital ( Site 1704)
Taichung, 40705, Taiwan
-
Taipei Veterans General Hospital ( Site 1703)
Taipei, 112, Taiwan
-
The Christie NHS Foundation Trust ( Site 1001)
Manchester, m20 4bx, United Kingdom
-
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro
Los Angeles, California, 90095, United States
-
UCSF Medical Center at Mission Bay ( Site 0108)
San Francisco, California, 94158, United States
-
UT Southwestern Medical Center ( Site 0110)
Dallas, Texas, 75390, United States
-
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Urologie ( Site 0405)
Dresden, Saxony, 01307, Germany
-
Universitätsklinikum Jena ( Site 0402)
Jena, Thuringia, 07747, Germany
-
Western General Hospital ( Site 1003)
Edinburgh, Midlothian, EH4 2XU, United Kingdom
-
Westmead Hospital ( Site 1501)
Westmead, New South Wales, 2145, Australia
-
Yale-New Haven Hospital-Yale Cancer Center ( Site 0102)
New Haven, Connecticut, 06510, United States
-
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Sit
Munich, Bavaria, 81675, Germany
Conditions
Explore the condition pages connected to this study.